Marksans Pharma’s arm gets UK MHRA nod for Bells Healthcare All in One Oral Solution

22 Feb 2022 Evaluate

Marksans Pharma’s wholly owned subsidiary -- Bell Sons & Co. (Druggists) has received UK MHRA’s grant for market authorization of Bells Healthcare All in One Oral Solution. Marksans will manufacture the products at its UK MHRA approved facility Bell Sons & Co. (Druggists) in UK. This is first generic approval by UK MHRA for the product.

Each 20 ml dose contains Paracetamol Ph. Eur. 500.0 mg, Guaifenesin Ph. Eur. 200.0 mg and Phenylephrine Hydrochloride Ph. Eur. 10.0 mg. Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs.

Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.


Marksans Pharma Share Price

183.95 -3.95 (-2.10%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×